Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 as Monotherapy in Patients With Hypercholesterolaemia (MENDEL): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Study Questions:

Does a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) lower lipids among patients with hypercholesterolemia who are not taking concurrent lipid-lowering therapy such as statins?